181 related articles for article (PubMed ID: 26134021)
21. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
22. Polycythemia vera is not initiated by JAK2V617F mutation.
Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
[TBL] [Abstract][Full Text] [Related]
23. JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice.
Means RT
Am J Med Sci; 2008 Oct; 336(4):327-9. PubMed ID: 18854675
[TBL] [Abstract][Full Text] [Related]
24. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
25. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
[TBL] [Abstract][Full Text] [Related]
26. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Bongartz H; Hessenkemper W; Müller C; Fensky M; Fritsch J; Mandel K; Behrmann I; Haan C; Fischer T; Feller SM; Schaper F
Cell Signal; 2017 Jul; 35():37-47. PubMed ID: 28365441
[TBL] [Abstract][Full Text] [Related]
27. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
28. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
[TBL] [Abstract][Full Text] [Related]
29. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
[TBL] [Abstract][Full Text] [Related]
30. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
[TBL] [Abstract][Full Text] [Related]
31. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
[TBL] [Abstract][Full Text] [Related]
32. Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.
Flosdorf N; Böhnke J; de Toledo MAS; Lutterbach N; Lerma VG; Graßhoff M; Olschok K; Gupta S; Tharmapalan V; Schmitz S; Götz K; Schüler HM; Maurer A; Sontag S; Küstermann C; Seré K; Wagner W; Costa IG; Brümmendorf TH; Koschmieder S; Chatain N; Castilho M; Schneider RK; Zenke M
Stem Cell Reports; 2024 Feb; 19(2):224-238. PubMed ID: 38278152
[TBL] [Abstract][Full Text] [Related]
33. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
Jamieson CH; Gotlib J; Durocher JA; Chao MP; Mariappan MR; Lay M; Jones C; Zehnder JL; Lilleberg SL; Weissman IL
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6224-9. PubMed ID: 16603627
[TBL] [Abstract][Full Text] [Related]
34. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
35. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.
Thurmes PJ; Steensma DP
Eur J Haematol; 2006 Jul; 77(1):57-60. PubMed ID: 16827884
[TBL] [Abstract][Full Text] [Related]
37. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
38. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.
Tsuruta-Kishino T; Koya J; Kataoka K; Narukawa K; Sumitomo Y; Kobayashi H; Sato T; Kurokawa M
Oncogene; 2017 Jun; 36(23):3300-3311. PubMed ID: 28068330
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
